Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 7/20 | 0.59 |
| ▸ | BRD4 | O60885 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | BRD2 | P25440 | 1/20 | 0.47 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.47 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8114228 | 0.91 | ADRA1D (0.61) | ADRA1DLMNAALDH1A1MAPTHPGD | |
| SCHEMBL31418340 | 0.91 | ADRA1D (0.57) | ADRA1DBRD4LMNAALDH1A1MAPT | |
| SCHEMBL15225647 | 0.87 | ADRA1D (0.64) | ADRA1DBRD4LMNAALDH1A1 | |
| SCHEMBL15241737 | 0.84 | BRD4 (0.54) | ADRA1DBRD4LMNAALDH1A1MAPT | |
| SCHEMBL18584756 | 0.83 | ADRA1D (0.60) | ADRA1DBRD4LMNAMAPTHPGD | |
| SCHEMBL11610011 | 0.83 | BRD4 (0.56) | BRD4LMNAALDH1A1NOTUMBRD2 | |
| SCHEMBL13307004 | 0.82 | ADRA1D (0.42) | ADRA1DBRD4LMNAALDH1A1MAPT | |
| SCHEMBL14460019 | 0.82 | BRD4 (0.69) | ADRA1DBRD4LMNAALDH1A1MAPT | |
| SCHEMBL12376660 | 0.81 | BRD4 (0.57) | ADRA1DBRD4LMNAALDH1A1MAPT | |
| SCHEMBL6235800 | 0.78 | ADRA1D (0.48) | ADRA1DBRD4LMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| CN-101522687-A | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA INC (US) | 2009-09-02 | — | — | CN | disclosed |
| EP-1989211-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | Array Biopharma, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008063202-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | ADRA1D 1892/4885BRD4 4102/4885LMNA 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.